TTrialPathMatch Me to Trials
← Back to trials
RecruitingSchizophreniaBipolar DisorderAlzheimer Disease

Neurofilament Light Chains and Cognitive Impairment in Chronic Psychiatric Disease

Eligible age

45–80 yrs

Accepts

All genders

Locations

0 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The validation of biomarkers allowing the discrimination of cognitive and behavioral disorders of psychiatric origin from those of neurodegenerative origin would facilitate diagnosis and improve patient management. Neurofilaments, which are markers of neuronal lysis, appear to be a promising biomarker. In a previous preliminary study, the investigators demonstrated significantly lower concentrations of neurofilaments in CSF of psychiatric patients compared to neurodegenerative diseases. The main objective of this study is to validate the plasma assay of neurofilament light chain as a biomarker for the differential diagnosis of psychiatric or neurodegenerative cognitive impairment. Other biomarkers of interest (Tau, TDP-43, GFAP and UCH-L1) will also be analyzed. A sub-part of this study will also focus on the retrospective analysis of the CSF/Plasma correlations of the different biomarkers mentioned above from tube bottom samples taken in routine care.

Sponsor: Hôpital le Vinatier

You may qualify if…

  • ✓ haven given written consent
  • ✓ Participants with psychiatric conditions:
  • ✓ Schizophrenia (DSM-V criteria) with or without cognitive involution
  • ✓ Bipolar disorder (DSM-V criteria) with or without cognitive involution
  • ✓ Participants with neurodegenerative disease:
  • ✓ probable or definite FTD (Rascovsky criteria 2011)
  • ✓ Biological Alzheimer's disease with typical CSF (NIA-AA 2011)

You may not qualify if…

  • ✕ Uninterviewable patient and/or missing history
  • ✕ History of recent or previous head trauma with loss of consciousness
  • ✕ History of ischemic or hemorrhagic stroke
  • ✕ Chronic alcoholism / chronic drug use
  • ✕ Progressive somatic pathology / severe metabolic disorder / poorly controlled epilepsy
  • ✕ Age \< 45 years
  • ✕ Age \> 80 years
  • ✕ Electroconvulsive therapy for less than 6 months

Source: ClinicalTrials.gov · NCT04946916 · last updated 2025-07-24

Neurofilament Light Chains and Cognitive Impairment in Chronic Psychia · TrialPath